(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 November 2010 (18.11.2010)

PCT

(10) International Publication Number
WO 2010/130726 A1

(51) International Patent Classification:
C07H 19/06 (2006.01) *A61K 31/7072* (2006.01)
C07H 19/10 (2006.01)

(21) International Application Number:
PCT/EP2010/056438

(22) International Filing Date:
11 May 2010 (11.05.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09160215.1 14 May 2009 (14.05.2009) EP

(71) Applicants *(for all designated States except US)*: **CENTOCOR ORTHO BIOTECH PRODUCTS L.P.** [US/US]; 430 Route 22 East, Bridgewater, New Jersey 08807 (US). **MEDIVIR AB** [SE/SE]; Lunastigen 7, S-141 44 Huddinge (SE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **JONCKERS, Tim, Hugo, Maria** [BE/BE]; Pastoor Wouterstraat 19 bus 5, B-2650 Edegem (BE). **RABOISSON, Pierre, Jean-Marie, Bernard** [FR/BE]; Rue Jolie 3, B-1331 Rosieres (BE). **VANDYCK, Koen** [BE/BE]; Deurnestraat 74, B-3583 Paal-Beringen (BE). **VAN HOOF, Steven, Maurice, Paula** [BE/BE]; Hundelgemsesteenweg 804, B-9820 Merelbeke (BE). **HU, Lili** [NL/BE]; Vrouw van Mechelenstraat 28, B-2800 Mechelen (BE). **TAHRI, Abdellah** [BE/BE]; Rue Maurice Albert Raskin 30, B-1070 Anderlecht (BE).

(74) Agent: **WANTE, Dirk**; Tibotec-Virco Comm. VA, J&J Patent Law Department, Generaal De Wittelaan L 11B 3, B-2800 Mechelen (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

[Continued on next page]


(54) Title: URACYL SPIROOXETANE NUCLEOSIDES



(I)



(II)



(III)

(57) Abstract: Compounds of the formula (I) including any possible stereoisomers thereof, wherein: R^4 is a monophosphate, diphosphate or triphosphate ester; or R^4 is formula (II) or formula (III), R^7 is optionally substituted phenyl, optionally substituted naphthyl, or optionally substituted indolyl; R^8 and R^8 are hydrogen, C_1-C_6alkyl, benzyl, or phenyl; or R^8 and R^8 form C_3-C_7cycloalkyl; R^9 is C_1-C_{10}alkyl, C_3-C_7cycloalkyl, phenyl or phenyl-C_1-C_6alkyl, wherein the phenyl moiety in phenyl or phenyl-C_1-C_6alkyl is optionally substituted; or a pharmaceutically acceptable salt or solvate thereof; pharmaceutical formulations and the use of compounds I as HCV inhibitors.

WO 2010/130726 A1

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*